University of Thessaly (UTH)
CD8 Τ κυτταρική απάντηση έναντι των αντιγόνων MAGE στον καρκίνο του πνεύμονα
Abstract
dc:descriptionOBJECTIVE The aim of cancer immunotherapy is to stimulate pre-existing anti-tumour specific CD8+ T cells, in order to recognise and destroy the cancer. Although such destruction has been described for a limited number of patients, the study of the interplayers of such an effect has never taken place in conjunction with normal individuals. This study was scheduled in order to determine in patients with lung cancer the magnitude and function of the pre-existing, naturally occurring cytolytic CD8+ T-cell responses against peptides of the most widely used cancer-testis antigens in cancer immunotherapy, namely MAGE-A1 and MAGE-A3 and compare these findings with those that might be unravelled in aged-matched healthy individuals.MATERIALS Peripheral blood mononuclear cells were collected from 15 patients with non-small cell lung carcinoma and 10 patients with small cell lung carcinoma upon diagnosis and 15 aged matched healthy individuals, expressing at least one of the HLA-A1, -A2, -A24 and/or HLA-B35 alleles. In 16 of the patients, cells were also collected 3-6 months post treatment with chemotherapy and/or radiotherapy. Finally, in 11 patients that underwent surgery for removal of their tumour, tumor infiltrating lymphocytes and tumor tissue were collected. METHODS The frequency of peptide-specific T cells was estimated using a sensitive method that combines HLA-multimer flow cytometric technology with a previous step of in vitro amplification under limiting dilution conditions. Amplified T cells were magnetically sorted and used to: (a) characterise their ability to lyse chromium labelled cells expressing the relevant antigens, (b) determine their TCR affinity against peptide loaded chromium labelled cells, (c) identify the expression of the differentiation molecules CD28, CD45RA, CD45RO and CCR7 by flow cytometry, (d) determine their ability to secrete IL-2, IL-4, IL-5, IL-10, IFN-γ and TNF-α after peptide specific stimulation, (e) determine the expression of Bcl-2 transcripts, and finally (f) determine the TcR Vβ sequence.RESULTS Anti-MAGE CD8 Τ cells were detected in the blood of both healthy individuals and lung cancer patients upon diagnosis. The cumulative frequency of circulating peptide-specific T cells was found to be higher in cancer patients (13±20.5 x 10-7) than normal individuals (1.8±1 x 10-7), varied widely amongst patients and was not affected by radiotherapy and/or chemotherapy. Amongst patients, the most frequent responses were those detected against MAGE-A3.Α2 and MAGE-A3.Α24 (36% και 44%, respectively), whereas 56% of normal individuals responded against the MAGE-A3.Α2 peptide. T cell responses against the other peptides were limited in both groups. Patients had similar numbers of anti-EBV T cells as did normal individuals. In none of the tumor infiltrating lymphocyte samples was an anti-MAGE T cell response detected despite the identification of anti-EBV T cells. Compared to normal individuals, CD8 T cells from patients presented with a reduced ability to lyse targets (p=0.013), proliferate to antigenic stimuli (p=0.041) and to bind the peptide-MHC complex with a high affinity (p=0.038). All anti-tumour specific T cells, irrespective of their origin, displayed a memory phenotype (CD28+/CD57-), expressed Bcl-2 and secreted ΙL-2, IL-4, IL-5, IFN-γ and TNF-α but not IL-10. CONCLUSION This study uncovered that cancer patients present with a wide variation in the frequency of peptide-specific pCTLs and this frequency differs greatly between tumor-antigen peptides. Furthermore, tumor-specific pCTLs of cancer patients present with functional differences when compared to those of healthy individuals. In the light of recent evidence, both of these findings (number and function) might have played a detrimental role in the limited success of current immunotherapy protocols and could represent an important determinant for the fate of cancer immunotherapy. Thus, improving our understanding as to what affects these parameters, promises to have a significant impact on the design of future cancer immunotherapy protocols.
Degree
thesis:*- Grantor dc:publisher
- University of Thessaly (UTH)
- Year dc:date
- 2010
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Ζαμανάκου, Μαρία
- Zamanakou, Maria
Subjects
dc:subject × 9Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/28947